x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Clinical Training Centres Fellowship Programme > Fellowship Programme - Doctors > National Institute of Oncology Budapest (Hungary)
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

National Institute of Oncology Budapest

Budapest, Hungary

Person responsible for CTC programme: Dr. Zoltán Takácsi-Nagy

Hospital overview

For more than half a century, the National Institute of Oncology (NIO) has been the epidemiological, organisational, methodological, treatment, research and training centre of oncology in Hungary. The Institute has 5 research and 9 clinical departments, and is the first Comprehensive Cancer Center (CCC) accredited by the OECI not only in Hungary, but also in the Central and Eastern European region. The NIO operates with 347 beds and provides treatment to approximately 16,000 patients annually. The Institute houses and manages the Hungarian National Cancer Registry. As a CCC, NIO also places a special emphasis on education and holds the chair of the Semmelweis University Department of Oncology. The Institute organises undergraduate education for medical students in oncology in Hungarian, English and German languages. Accredited postgraduate medical training is also offered by NIO, which is open to professionals from other institutions. The centre also provides education for nurses and other health care professionals. The NIO also participates in several projects of the EU Cancer Mission and the Europe Beating Cancer Plan such as the 4.UNCAN.eu, CRanE, JANE, eCAN, PCM4EU, OriON, ECHoS, EUonQol, and the CCI4EU project.

 

CTC programmes offered

1. Cyberknife and stereotactic radiotherapy
Discipline:

Radiotherapy
Programme mentor:

Levente Jánváry M.D.
Duration: 3 months
Type: Residency and Observership
Language requirements: Good knowledge of English required
Programme description:

Getting to know the indication, preparation, treatment process, side effects, complication Stereotactic radiotherapy of different metastatic diseases (brain, lung, liver, bone metastases) or certain solid tumours with linear accelerator or Cyberknife (8 weeks) Curative treatment of early stage, low risk prostate cancer and postoperative treatment of the tumour bed in breast cancer with Cyberknife (2 weeks) Radiotherapy of recurrences (e.g. head and neck) (2 weeks)

2. Robotic surgery
Discipline: Surgical oncology
Programme mentors: Prof. Péter Tenke MD, DSc; Zoltán Novák MD, PhD; Tamás Mersich MD, PhD
Duration: 3 months 
Type: Residency and Observership 
Language requirements: Good knowledge of English required
Programme description:

Getting to know the indication, the advantage, the technique and complications of the robotic surgery.

Robotic surgery of urological tumours (4 weeks)

Robotic surgery of gynaecological tumours (4 weeks)

Robotic surgery of abdominal tumours (3 weeks)

3. Chemotherapy, targeted (biological) therapy and immunotherapy of solid tumours and lymphoproliferative diseases
Discipline:

Medical oncology
Programme mentors:

Lajos Géczi MD, PhD; Gábor Rubovszky MD, PhD; András Masszi MD, PhD; Erika Tóth MD, PhD
Duration:

3 months
Type: Residency and Observership 
Language requirements:  Good knowledge of English required
Programme description: 

Indication of chemotherapy in different solid tumours, complications and their management. (3 weeks)

Indication of targeted therapy in different solid tumours, complications and their management. (3 weeks)

Indication of immunotherapy in different solid tumours, complications and their management. (2 weeks)

Indication of systemic therapy of lymphoproliferative disease, complications and their management. (2 weeks)

Molecular pathology examinations. (2 weeks)

4. Rare tumours therapy
Discipline:  Medical oncology
Programme mentor: 

Gábor Rubovszky MD, PhD
Duration:  1 month
Type:  Residency and Observership 
Language requirements:   Good knowledge of English required
Programme description:  

Patients with rare cancers who cannot be treated with available professional guidelines.

In line with international standards of complex oncotherapy care, our Institute has been accepted into the Orphanet system for rare diseases and the Rare Tumour Network coordinated by the European Association of Cancer Centres, as well as the Rare Gynaecological Tumour Network.